Celgosivir
| INN | |
|---|---|
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | Investigational |
| CAS Number | |
| PubChem | 60734 |
| DrugBank | |
| ChemSpider | 54737 |
| KEGG | |
Celgosivir, in development by Migenix for the treatment of hepatitis C virus (HCV) infection, is an oral prodrug of the natural product castanospermine that inhibits alpha-glucosidase I, an enzyme that plays a critical role in viral maturation by initiating the processing of the N-linked oligosaccharides of viral envelope glycoproteins. Celgosivir is well absorbed in vitro and in vivo, and is rapidly converted to castanospermine. Celgosivir has a novel mechanism of action (preventing the glycosylation of viral proteins by the host), and demonstrates broad antiviral activity in vitro.<ref name=Durantel>,
Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection, Current Opinion in Investigational Drugs, 2009, Vol. 10(Issue: 8), pp. 860–70, PMID: 19649930,</ref>
Clinical trials
Celgosivir is not efficient as a monotherapy for the treatment of HCV, but has demonstrated a synergistic effect in combination with pegylated interferon alfa-2b plus ribavirin, both in vitro and in phase II clinical trials that last up to 1 year in patients with chronic HCV infection. Celgosivir may prove to be a valuable component for combination therapy and may help to prevent the apparition of drug resistance. Long-term toxicity studies are necessary to confirm the safety of celgosivir in humans.<ref name=Durantel/>
Although generally safe and well tolerated, celgosivir does not seem to reduce viral load or fever burden in patients with dengue fever.<ref>,
Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): A phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial, The Lancet Infectious Diseases, 2014, Vol. 14(Issue: 8), pp. 706, DOI: 10.1016/S1473-3099(14)70730-3, PMID: 24877997,</ref>
References
<references group="" responsive="1"></references>
External links
Ad. Transform your life with W8MD's Budget GLP-1 injections from $29.99


W8MD offers medical weight loss programs including NYC medical weight loss and Philadelphia medical weight loss offering:
- Affordable GLP1 shots (generic and brand names) such as
- Wegovy NYC (Semaglutide)
- Zepbound NYC /
- Learn more: Budget GLP1 weight loss injections NYC & Philadelphia GLP1 weight loss shots
- Most insurances accepted
- Lowest cost GLP1 weight loss NYC such as Semaglutide starting from $29.99/week and $45.00/week (Tirzepatide) with insurance.
- Prescription weight loss NYC including:
NYC weight loss doctor appointmentsNYC weight loss doctor appointments
Start your physician weight loss journey today at our:
- NYC medical weight loss
- Philadelphia medical weight loss
- Call 718-946-5500 for NYC or 215-676-2334 for Philadelphia
- Tags:
Budget glp1 weight loss NYC,
Zepbound NYC,
Philadelphia medical weight loss,
Wegovy NYC,
Zepbound Philadelphia,
Budget GLP1 shots Philadelphia
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
